Stock AVIR ATEA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
3.31 USD -2.07% Intraday chart for Atea Pharmaceuticals, Inc. -3.78% +8.52%
06-05 Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 CI
05-22 Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,452 742.9 400.6 254.5 278.8 - -
Enterprise Value (EV) 1 2,602 -21.44 -246.1 -321.2 -239.3 -124.8 -112.3
P/E ratio -81.9 x 6.53 x -3.46 x -1.87 x -1.19 x -1.11 x -1.63 x
Yield - - - - - - -
Capitalization / Revenue 71 x 2.11 x - - - 6.16 x 2.55 x
EV / Revenue 53.5 x -0.06 x - - - -2.76 x -1.03 x
EV / EBITDA -236 x -0.15 x 1.89 x 1.96 x 1.06 x 0.61 x 0.56 x
EV / FCF 8.77 x 0.25 x 2 x 3.76 x 1.91 x 0.54 x 0.52 x
FCF Yield 11.4% 406% 50% 26.6% 52.2% 186% 192%
Price to Book 1.65 x 1.05 x 0.63 x 0.46 x 0.77 x 1.4 x 1.9 x
Nbr of stocks (in thousands) 82,617 83,103 83,288 83,436 84,223 - -
Reference price 2 41.78 8.940 4.810 3.050 3.310 3.310 3.310
Announcement Date 21-03-30 22-02-28 23-02-28 24-02-28 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 48.63 351.4 - - - 45.24 109.4
EBITDA 1 - -11.01 138.4 -130.4 -163.7 -226.1 -206 -199.3
EBIT 1 - -11.03 138.4 -130.6 -164.2 -227.5 -217.4 -199.4
Operating Margin - -22.68% 39.38% - - - -480.6% -182.35%
Earnings before Tax (EBT) 1 - -10.95 138.6 -119.5 -134.9 -233.4 -250.9 -253
Net income 1 -14.03 -10.95 121.2 -115.9 -136 -233.8 -251 -252.6
Net margin - -22.51% 34.49% - - - -554.79% -231.01%
EPS 2 -1.390 -0.5100 1.370 -1.390 -1.630 -2.783 -2.974 -2.027
Free Cash Flow 1 - 296.7 -87.01 -122.9 -85.4 -125 -232 -216
FCF margin - 610.1% -24.76% - - - -512.82% -197.53%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 20-06-19 21-03-30 22-02-28 23-02-28 24-02-28 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 192.2 - - - - - - - - - - - - - -
EBITDA 1 121.2 -42.17 -32.25 -16.18 -39.8 -41.46 -35.13 -40.68 -46.47 -69.7 -72 -73 -70 - -
EBIT 1 121.2 -42.18 -32.3 -16.28 -39.9 -41.57 -35.24 -40.78 -46.57 -69.81 -70.28 -58.78 -58.78 - -
Operating Margin 63.06% - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 121.2 -42.08 -31.22 -11.9 -34.31 -35.27 -27.93 -32.92 -38.82 -62.94 -64.57 -53.32 -53.02 - -
Net income 1 117.1 -42.08 -31.34 -8.066 -34.43 -35.47 -28.18 -33.14 -39.16 -63.17 -64.57 -53.32 -53.02 - -
Net margin 60.95% - - - - - - - - - - - - - -
EPS 2 1.320 -0.5100 -0.3800 -0.1000 -0.4100 -0.4300 -0.3400 -0.4000 -0.4700 -0.7500 -0.7662 -0.6320 -0.6322 -0.6000 -0.6600
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 22-02-28 22-05-10 22-08-08 22-11-07 23-02-28 23-05-08 23-08-08 23-11-08 24-02-28 24-05-14 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 850 764 647 576 518 404 391
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - 297 -87 -123 -85.4 -125 -232 -216
ROE (net income / shareholders' equity) - -4.39% 19.3% -17.2% -22.7% -45.1% -77.4% -173%
ROA (Net income/ Total Assets) - -2.47% 14.8% -16.1% -21.6% -47.4% -68.6% -87.2%
Assets 1 - 442.9 818.3 719.8 630.8 493.6 366 289.8
Book Value Per Share 2 - 25.40 8.540 7.700 6.660 4.320 2.370 1.740
Cash Flow per Share - - - - - - - -
Capex 1 - - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 20-06-19 21-03-30 22-02-28 23-02-28 24-02-28 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
3.31 USD
Average target price
5.5 USD
Spread / Average Target
+66.16%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ATEA PHARMACEUTICALS, INC. Stock Atea Pharmaceuticals, Inc.
+8.52% 279M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AVIR Stock
  4. Financials Atea Pharmaceuticals, Inc.